# Nuwellis, Inc.: financial statements, quarterly

NUWE · Nasdaq · CIK 1506492 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nuwe.md) · [Financials](/companies/nuwe/financials.md) · [Filings](/companies/nuwe/filings.md) · [Insiders](/companies/nuwe/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nuwe/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.4](/filings/0001140361-24-046166.md) | [2.6 d](/filings/0001140361-25-008124.md) | [1.9](/filings/0001140361-25-018676.md) | [2.2](/filings/0001140361-25-031209.md) | [2.4](/filings/0001140361-25-041651.md) | [2.3 d](/filings/0001140361-26-009080.md) | [1.9](/filings/0001140361-26-021649.md) | [1.7](/filings/0001140361-26-032810.md) | [2.2](/filings/0001140361-25-041651.md) | [2.4 d](/filings/0001140361-26-009080.md) | [2.4](/filings/0001140361-26-021649.md) | [2.0](/filings/0001140361-26-032810.md) |
| Cost of revenue | $m | [1.0](/filings/0001140361-24-046166.md) | [1.2 d](/filings/0001140361-25-008124.md) | [0.7](/filings/0001140361-25-018676.md) | [0.7](/filings/0001140361-25-031209.md) | [0.7](/filings/0001140361-25-041651.md) | [1.0 d](/filings/0001140361-26-009080.md) | [0.8](/filings/0001140361-26-021649.md) | [0.8](/filings/0001140361-26-032810.md) | [0.8](/filings/0001140361-25-041651.md) | [0.8 d](/filings/0001140361-26-009080.md) | [0.7](/filings/0001140361-26-021649.md) | [0.5](/filings/0001140361-26-032810.md) |
| Gross profit | $m | [1.4](/filings/0001140361-24-046166.md) | [1.4 d](/filings/0001140361-25-008124.md) | [1.2](/filings/0001140361-25-018676.md) | [1.5](/filings/0001140361-25-031209.md) | [1.7](/filings/0001140361-25-041651.md) | [1.4 d](/filings/0001140361-26-009080.md) | [1.1](/filings/0001140361-26-021649.md) | [1.0](/filings/0001140361-26-032810.md) | [1.4](/filings/0001140361-25-041651.md) | [1.7 d](/filings/0001140361-26-009080.md) | [1.7](/filings/0001140361-26-021649.md) | [1.5](/filings/0001140361-26-032810.md) |
| Research and development | $m | [1.1](/filings/0001140361-24-046166.md) | [1.4 d](/filings/0001140361-25-008124.md) | [1.3](/filings/0001140361-25-018676.md) | [0.6](/filings/0001140361-25-031209.md) | [0.5](/filings/0001140361-25-041651.md) | [0.8 d](/filings/0001140361-26-009080.md) | [0.6](/filings/0001140361-26-021649.md) | [0.7](/filings/0001140361-26-032810.md) | [0.6](/filings/0001140361-25-041651.md) | [0.9 d](/filings/0001140361-26-009080.md) | [1.7](/filings/0001140361-26-021649.md) | [0.9](/filings/0001140361-26-032810.md) |
| Selling, general and administrative | $m | [3.4](/filings/0001140361-24-046166.md) | [3.6 d](/filings/0001140361-25-008124.md) | [4.6](/filings/0001140361-25-018676.md) | [3.2](/filings/0001140361-25-031209.md) | [2.7](/filings/0001140361-25-041651.md) | [2.9 d](/filings/0001140361-26-009080.md) | [3.6](/filings/0001140361-26-021649.md) | [3.2](/filings/0001140361-26-032810.md) | [3.5](/filings/0001140361-25-041651.md) | [3.2 d](/filings/0001140361-26-009080.md) | [4.5](/filings/0001140361-26-021649.md) | [3.7](/filings/0001140361-26-032810.md) |
| Operating income | $m | [(3.2)](/filings/0001140361-24-046166.md) | [(3.6) d](/filings/0001140361-25-008124.md) | [(4.7)](/filings/0001140361-25-018676.md) | [(2.3)](/filings/0001140361-25-031209.md) | [(1.5)](/filings/0001140361-25-041651.md) | [(2.4) d](/filings/0001140361-26-009080.md) | [(3.1)](/filings/0001140361-26-021649.md) | [(2.9)](/filings/0001140361-26-032810.md) | [(2.7)](/filings/0001140361-25-041651.md) | [(2.4) d](/filings/0001140361-26-009080.md) | [(4.6)](/filings/0001140361-26-021649.md) | [(3.2)](/filings/0001140361-26-032810.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001140361-24-046166.md) | [0.0 d](/filings/0001140361-25-008124.md) | [0.0](/filings/0001140361-25-018676.md) | [0.0](/filings/0001140361-25-031209.md) | [0.0](/filings/0001140361-25-041651.md) | [0.0 d](/filings/0001140361-26-009080.md) | [0.0](/filings/0001140361-26-021649.md) | [0.0](/filings/0001140361-26-032810.md) | [0.0](/filings/0001140361-25-041651.md) | [0.0 d](/filings/0001140361-26-009080.md) | [0.0](/filings/0001140361-26-021649.md) | [0.0](/filings/0001140361-26-032810.md) |
| Net income | $m | [(3.4)](/filings/0001140361-24-046166.md) | [(5.5) d](/filings/0001140361-25-008124.md) | [(4.3)](/filings/0001140361-25-041651.md) | [(7.7)](/filings/0001140361-25-041651.md) | [2.4](/filings/0001140361-25-041651.md) | [(1.5) d](/filings/0001140361-26-009080.md) | [(3.0)](/filings/0001140361-26-032810.md) | [(12.6)](/filings/0001140361-26-032810.md) | [0.5](/filings/0001140361-25-041651.md) | [(2.4) d](/filings/0001140361-26-009080.md) | [(4.5)](/filings/0001140361-26-032810.md) | [(4.8)](/filings/0001140361-26-032810.md) |
| Diluted EPS | $ per share | [(63.27)](/filings/0001140361-24-046166.md) | not reported | [(24.11)](/filings/0001140361-25-018676.md) | [(791.82)](/filings/0001140361-25-031209.md) | [73.23](/filings/0001140361-25-041651.md) | not reported | [(28.93)](/filings/0001140361-26-021649.md) | [(2134.19)](/filings/0001140361-26-032810.md) | [0.56](/filings/0001140361-25-041651.md) | not reported | [(2.19)](/filings/0001140361-26-021649.md) | [(26.64)](/filings/0001140361-26-032810.md) |
| Basic EPS | $ per share | [(63.27)](/filings/0001140361-24-046166.md) | not reported | [(24.11)](/filings/0001140361-25-018676.md) | [(791.82)](/filings/0001140361-25-031209.md) | [73.23](/filings/0001140361-25-041651.md) | not reported | [(28.93)](/filings/0001140361-26-021649.md) | [(2134.19)](/filings/0001140361-26-032810.md) | [0.56](/filings/0001140361-25-041651.md) | not reported | [(2.19)](/filings/0001140361-26-021649.md) | [(26.64)](/filings/0001140361-26-032810.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.9](/filings/0001140361-23-051814.md) | [3.8](/filings/0001140361-25-008124.md) | [1.4](/filings/0001140361-24-024996.md) | [1.0](/filings/0001140361-24-037113.md) | [1.9](/filings/0001140361-24-046166.md) | [5.1](/filings/0001140361-26-009080.md) | [2.6](/filings/0001140361-25-018676.md) | [4.5](/filings/0001140361-25-031209.md) | [3.1](/filings/0001140361-25-041651.md) | [1.1](/filings/0001140361-26-032810.md) | [2.1](/filings/0001140361-26-021649.md) | [3.9](/filings/0001140361-26-032810.md) |
| Current assets | $m | [9.6](/filings/0001140361-23-051814.md) | [8.2](/filings/0001140361-25-008124.md) | [5.2](/filings/0001140361-24-024996.md) | [4.8](/filings/0001140361-24-037113.md) | [5.5](/filings/0001140361-24-046166.md) | [8.9](/filings/0001140361-26-009080.md) | [6.1](/filings/0001140361-25-018676.md) | [8.4](/filings/0001140361-25-031209.md) | [7.2](/filings/0001140361-25-041651.md) | [5.2](/filings/0001140361-26-032810.md) | [5.8](/filings/0001140361-26-021649.md) | [7.9](/filings/0001140361-26-032810.md) |
| Total assets | $m | [11.4](/filings/0001140361-23-051814.md) | [9.8](/filings/0001140361-25-008124.md) | [6.7](/filings/0001140361-24-024996.md) | [6.2](/filings/0001140361-24-037113.md) | [6.7](/filings/0001140361-24-046166.md) | [9.9](/filings/0001140361-26-009080.md) | [7.0](/filings/0001140361-25-018676.md) | [9.2](/filings/0001140361-25-031209.md) | [8.0](/filings/0001140361-25-041651.md) | [6.1](/filings/0001140361-26-032810.md) | [7.0](/filings/0001140361-26-021649.md) | [9.1](/filings/0001140361-26-032810.md) |
| Current liabilities | $m | [3.0](/filings/0001140361-23-051814.md) | [3.2](/filings/0001140361-25-008124.md) | [4.3](/filings/0001140361-24-024996.md) | [4.0](/filings/0001140361-24-037113.md) | [2.7](/filings/0001140361-24-046166.md) | [2.6](/filings/0001140361-26-009080.md) | [2.7](/filings/0001140361-25-018676.md) | [3.9](/filings/0001140361-25-031209.md) | [3.5](/filings/0001140361-25-041651.md) | [3.0](/filings/0001140361-26-032810.md) | [3.7](/filings/0001140361-26-021649.md) | [4.0](/filings/0001140361-26-032810.md) |
| Total liabilities | $m | [3.6](/filings/0001140361-23-051814.md) | [6.6](/filings/0001140361-25-008124.md) | [5.8](/filings/0001140361-24-024996.md) | [13.0](/filings/0001140361-24-037113.md) | [3.5](/filings/0001140361-24-046166.md) | [3.3](/filings/0001140361-26-009080.md) | [3.4](/filings/0001140361-25-018676.md) | [18.2](/filings/0001140361-25-031209.md) | [4.1](/filings/0001140361-25-041651.md) | [3.5](/filings/0001140361-26-032810.md) | [4.3](/filings/0001140361-26-021649.md) | [11.2](/filings/0001140361-26-032810.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.8](/filings/0001140361-24-046166.md) | [3.0](/filings/0001140361-26-009080.md) | [0.9](/filings/0001140361-25-041651.md) | [(6.8)](/filings/0001140361-25-041651.md) | [3.2](/filings/0001140361-25-041651.md) | [6.5](/filings/0001140361-26-032810.md) | [3.6](/filings/0001140361-26-032810.md) | [(9.0)](/filings/0001140361-26-032810.md) | [3.9](/filings/0001140361-25-041651.md) | [2.6](/filings/0001140361-26-032810.md) | [2.7](/filings/0001140361-26-032810.md) | [(2.1)](/filings/0001140361-26-032810.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,825) d](/filings/0001140361-24-046166.md) | [(2,754) d](/filings/0001140361-25-008124.md) | [(2,862)](/filings/0001140361-25-018676.md) | [(2,754) d](/filings/0001140361-25-031209.md) | [(2,471) d](/filings/0001140361-25-041651.md) | [(1,504) d](/filings/0001140361-26-009080.md) | [(2,536)](/filings/0001140361-26-021649.md) | [(2,097) d](/filings/0001140361-26-032810.md) | [(3,147) d](/filings/0001140361-25-041651.md) | [(3,030) d](/filings/0001140361-26-009080.md) | [(3,112)](/filings/0001140361-26-021649.md) | [(3,175) d](/filings/0001140361-26-032810.md) |
| Capital expenditure | $k | [121 d](/filings/0001140361-24-046166.md) | [(36.0) d](/filings/0001140361-25-008124.md) | [29.0](/filings/0001140361-25-018676.md) | [24.0 d](/filings/0001140361-25-031209.md) | [(16.0) d](/filings/0001140361-25-041651.md) | [23.0 d](/filings/0001140361-26-009080.md) | [0.0](/filings/0001140361-26-021649.md) | [4.0 d](/filings/0001140361-26-032810.md) | [98.0 d](/filings/0001140361-25-041651.md) | [(12.0) d](/filings/0001140361-26-009080.md) | [30.0](/filings/0001140361-26-021649.md) | [9.0 d](/filings/0001140361-26-032810.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [105](/filings/0001140361-23-051814.md) | [1,126](/filings/0001140361-24-024996.md) | [37.9](/filings/0001140361-24-037113.md) | [53.3](/filings/0001140361-24-046166.md) | [180](/filings/0001140361-25-018676.md) | [9.8](/filings/0001140361-25-031209.md) | [205](/filings/0001140361-25-041651.md) | [104](/filings/0001140361-26-021649.md) | [5.9](/filings/0001140361-26-032810.md) | [836](/filings/0001140361-25-041651.md) | [2,075](/filings/0001140361-26-021649.md) | [181](/filings/0001140361-26-032810.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,647,264 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001140361-26-032810.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.